{
  "items": "29",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Ginkgo Bioworks Holdings Insider Sellers Miss The Bus As Stock Jumps 10.0%",
      "url": "https://www.sahmcapital.com/news/content/ginkgo-bioworks-holdings-insider-sellers-miss-the-bus-as-stock-jumps-100-2025-12-26",
      "time_published": "20251227T021057",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Ginkgo Bioworks Holdings stock jumped 10.0% recently, suggesting that an insider who sold US$220k worth of shares at an average price of US$10.99 over the past year may have made the correct decision. Despite the stock gain, the selling price was higher than the current price, indicating that holding the stock would have resulted in a lower value for their investment today. Insiders currently own 17% of Ginkgo Bioworks Holdings shares, valued at approximately US$86m.",
      "banner_image": "NULL",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.911554"
        },
        {
          "topic": "finance",
          "relevance_score": "0.701572"
        }
      ],
      "overall_sentiment_score": 0.106179,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.122257",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks (DNA) Shares Rise On New Cancer Screening Approach Plans",
      "url": "https://www.sahmcapital.com/news/content/ginkgo-bioworks-dna-shares-rise-on-new-cancer-screening-approach-plans-2025-12-22",
      "time_published": "20251223T080936",
      "authors": [
        "Benzinga News"
      ],
      "summary": "Ginkgo Bioworks (NYSE: DNA) shares rose over 8% after announcing a strategic partnership with Carnegie Mellon University under the Advanced Research Projects Agency for Health (ARPA-H). This collaboration supports the POSEIDON program, focusing on developing an orally administered pill for early cancer detection through engineered sensors and at-home urine testing. Ginkgo will apply its cell and enzyme engineering expertise to advance these diagnostic tools.",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/22152926/Screenshot-2025-12-22-at-3.29.13%E2%80%AFPM-1024x197.png",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.817775"
        }
      ],
      "overall_sentiment_score": 0.482468,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.471664",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach",
      "url": "https://www.sahmcapital.com/news/content/ginkgo-bioworks-partners-with-carnegie-mellon-university-to-develop-innovative-new-cancer-screening-approach-2025-12-22",
      "time_published": "20251223T080936",
      "authors": [],
      "summary": "Ginkgo Bioworks has partnered with Carnegie-Mellon University (CMU) on an ARPA-H award to develop a novel cancer screening approach. This initiative, part of the POSEIDON program, aims to create an orally administered pill with engineered tumor-targeting sensors and a user-friendly at-home urine testing device for early cancer detection. Ginkgo will contribute its cell and enzyme engineering expertise to this interdisciplinary project.",
      "banner_image": "https://mma.prnewswire.com/media/1583909/Ginkgo_Logo_Lockup.jpg",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "technology",
          "relevance_score": "0.843795"
        }
      ],
      "overall_sentiment_score": 0.458316,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.490500",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Price-Driven Insight from (DNA) for Rule-Based Strategy",
      "url": "https://news.stocktradersdaily.com/news_release/24/Price-Driven_Insight_from_DNA_for_Rule-Based_Strategy_121525022402_1765783442.html",
      "time_published": "20251215T022400",
      "authors": [
        "Joseph H.",
        "Thomas H. Kee Jr."
      ],
      "summary": "This article provides a price-driven insight into Ginkgo Bioworks Holdings Inc. Class A (NYSE: DNA) for rule-based strategies. It highlights strong sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 37.3% gain. The piece also outlines institutional trading strategies tailored to various risk profiles, including position trading, momentum breakout, and risk hedging strategies, with specific entry zones, targets, and stop losses.",
      "banner_image": "https://news.stocktradersdaily.com/media/686387_DNA_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.948725"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.716356"
        }
      ],
      "overall_sentiment_score": 0.805737,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.808881",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy",
      "url": "https://www.sahmcapital.com/news/content/strmbio-awarded-arpa-h-contract-to-advance-megakaryocyte-derived-vesicle-platform-for-in-vivo-cell-engineering-and-gene-therapy-2025-12-03",
      "time_published": "20251204T040038",
      "authors": [
        "NULL"
      ],
      "summary": "STRM.BIO has been awarded an ARPA-H contract worth up to $8.4 million to advance its megakaryocyte-derived extracellular vesicle (MV) delivery platform. This funding will support the development of in vivo cell engineering and gene therapy, specifically for immune cell engineering. STRM.BIO will lead a collaboration with Ginkgo Bioworks, the University of British Columbia, and Advanced Bioprocess Services to develop in vivo CAR-T therapeutics.",
      "banner_image": "https://mma.prnewswire.com/media/2295649/STRM_BIO_01_Logo.jpg",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932391"
        },
        {
          "topic": "technology",
          "relevance_score": "0.715474"
        }
      ],
      "overall_sentiment_score": 0.418046,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "0.948176",
          "ticker_sentiment_score": "0.449763",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Why Investors Shouldn't Be Surprised By Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 39% Share Price Plunge",
      "url": "https://www.sahmcapital.com/news/content/why-investors-shouldnt-be-surprised-by-ginkgo-bioworks-holdings-incs-nysedna-39-share-price-plunge-2025-11-17",
      "time_published": "20251117T040038",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has seen a significant share price drop, but its current price-to-sales (P/S) ratio of 2.5x, below the industry average of 3.4x, suggests it might be undervalued. This low P/S ratio is likely due to the company's declining revenue growth, which fell by 17% last year and 66% over three years, while analysts forecast only 3.5% growth for the next year, lower than the broader industry's 5.6%. Investors' pessimism about future revenue prospects appears to be the main factor contributing to the depressed P/S and stagnant share price.",
      "banner_image": "https://images.simplywall.st/asset/chart/130407341-ps-multiple-vs-industry-1-dark-2/1763374549801",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.905019"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.841344"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.726129"
        }
      ],
      "overall_sentiment_score": -0.257495,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.262584",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Institutional shareholders may be less affected by Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) pullback last week after a year of 2.2% returns",
      "url": "https://www.sahmcapital.com/news/content/institutional-shareholders-may-be-less-affected-by-ginkgo-bioworks-holdings-incs-nysedna-pullback-last-week-after-a-year-of-22-returns-2025-11-10",
      "time_published": "20251110T040038",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Institutional investors, holding 59% of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), experienced a 30% drop last week but were mitigated by 2.2% returns over the past year. The concentration of ownership, with the top 11 shareholders owning 52%, suggests that their trading decisions significantly impact the stock. The article also highlights insider ownership and the general public's 15% stake, noting the importance of considering these factors alongside analyst forecasts for future performance.",
      "banner_image": "NULL",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.826311"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.925115"
        }
      ],
      "overall_sentiment_score": -0.118384,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.124186",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program",
      "url": "https://www.sahmcapital.com/news/content/ginkgo-bioworks-in-partnership-with-strmbio-and-university-of-british-columbia-in-project-to-develop-in-vivo-car-therapies-under-arpa-hs-embody-program-2025-10-23",
      "time_published": "20251023T150000",
      "authors": [],
      "summary": "Ginkgo Bioworks announced a collaboration with STRM.BIO and the University of British Columbia under ARPA-H's EMBODY program to develop in vivo CAR therapies for autoimmune diseases. This partnership, called \"INVITE-ME,\" will leverage Ginkgo's RNA construct design expertise and STRM.BIO's proprietary megakaryocyte-derived extracellular vesicle delivery system to create transformative treatments for conditions like SLE and MG. The goal is to engineer T cells within the body to eliminate autoreactive immune cells, potentially offering durable therapies without ex vivo manipulation.",
      "banner_image": null,
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "technology",
          "relevance_score": "0.836348"
        }
      ],
      "overall_sentiment_score": 0.417233,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "0.906543",
          "ticker_sentiment_score": "0.421418",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks CFO Coen sells shares worth $17907",
      "url": "https://www.investing.com/news/insider-trading-news/ginkgo-bioworks-cfo-coen-sells-shares-worth-17907-93CH-4300282",
      "time_published": "20251021T170300",
      "authors": [
        "Investing.com"
      ],
      "summary": "Ginkgo Bioworks CFO Steven P. Coen sold 1,312 shares of Class A Common Stock for $17,907 on October 17, 2025, while also acquiring 2,547 shares through restricted stock units the day prior. This transaction comes as the company's shares have surged 80% over six months, despite recent disappointing Q2 2025 earnings and a proposed settlement for stockholder derivative actions. The stock is considered undervalued by InvestingPro analysis, and the next earnings report is due November 7.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.927704"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.828343"
        },
        {
          "topic": "finance",
          "relevance_score": "0.703459"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.616953"
        }
      ],
      "overall_sentiment_score": -0.228472,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.224943",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks Holdings, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo",
      "url": "https://www.marketsmojo.com/news/stocks-in-action/ginkgo-bioworks-holdings-inc-technical-trend-changes-from-bullish-to-mildly-bullish-amid-price-fluctuations-3620030",
      "time_published": "20251014T174245",
      "authors": [],
      "summary": "Ginkgo Bioworks Holdings, Inc. (DNA) has seen a stock re-evaluation, with its stock price at $13.16. The company boasts a 79.54% return over the past year, significantly outperforming the S&P 500. Despite mixed technical indicators, Ginkgo shows resilience with strong year-to-date performance and high institutional holdings.",
      "banner_image": "https://i.marketsmojo.com/newsimg/2025/10/GinkgoBioworksH_technicaldot_3620030.png",
      "source": "Markets Mojo",
      "category_within_source": "General",
      "source_domain": "Markets Mojo",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.900544"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.816096"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.703213"
        },
        {
          "topic": "economy_macro",
          "relevance_score": "0.416245"
        }
      ],
      "overall_sentiment_score": 0.004251,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "0.300536",
          "ticker_sentiment_score": "0.020378",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo",
      "url": "https://www.marketsmojo.com/news/stocks-in-action/ginkgo-bioworks-holdings-inc-technical-trend-changes-from-mildly-bullish-to-bullish-amid-strong-market-performance-3601429",
      "time_published": "20251012T195606",
      "authors": [
        "NULL"
      ],
      "summary": "Ginkgo Bioworks Holdings, Inc. has undergone a stock evaluation revision due to changing market conditions, showcasing significant year-to-date and annual returns that outperform the S&P 500. While technical indicators like MACD and moving averages show bullish trends, KST and Bollinger Bands present a mixed to mildly bearish outlook. The company's strong market performance is highlighted by a 51.43% year-to-date return and 78.51% over the past year.",
      "banner_image": "https://i.marketsmojo.com/newsimg/2025/10/GinkgoBioworksH_technicaldot_3601429.png",
      "source": "Markets Mojo",
      "category_within_source": "General",
      "source_domain": "Markets Mojo",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.935895"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.830151"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.746714"
        }
      ],
      "overall_sentiment_score": 0.033274,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "0.330409",
          "ticker_sentiment_score": "0.039844",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks: Ginkgo Bioworks Holdings, Inc. - Reverse Split Option Symbol: DNA New Symbol: DNA1",
      "url": "https://news.futunn.com/en/notice/300792545/ginkgo-bioworks-ginkgo-bioworks-holdings-inc-reverse-split-option-symbol",
      "time_published": "20241231T235959",
      "authors": [],
      "summary": "This document announces a reverse stock split for Ginkgo Bioworks Holdings, Inc. The option symbol for the company will change from DNA to DNA1. This change indicates a corporate action related to the company's stock.",
      "banner_image": null,
      "source": "\u5bcc\u9014\u725b\u725b",
      "category_within_source": "General",
      "source_domain": "\u5bcc\u9014\u725b\u725b",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.832155"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.701880"
        }
      ],
      "overall_sentiment_score": 0.026778,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "0.311779",
          "ticker_sentiment_score": "0.044056",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is It Too Late To Buy Ginkgo Bioworks Stock?",
      "url": "https://www.timothysykes.com/news/ginkgo-bioworks-holdings-inc-class-a-is-it-too-late-to-buy-ginkgo-bioworks-stock-2024_09_17/",
      "time_published": "20240917T040038",
      "authors": [
        "Timothy Sykes",
        "Jack Kellogg",
        "Ellis Hobbs"
      ],
      "summary": "Ginkgo Bioworks Holdings Inc. Class A (NYSE: DNA) saw a 10.11% surge in stock price fueled by a significant contract with the CDC for a traveler-based genomic surveillance program and regaining compliance with the NYSE minimum bid price rule. Despite substantial R&D spending leading to current net losses, the company maintains strong liquidity and a strategic focus on long-term growth in bioengineering. Investors are reacting positively to these developments, seeing them as validation of Ginkgo's scientific prowess and future potential, even as profitability remains a future goal.",
      "banner_image": "https://content.timothysykes.com/cdn-cgi/image/quality=90,format=webp,width=740/https://content.timothysykes.com/wp-content/uploads/2024/09/watermarked_DNA.png",
      "source": "www.timothysykes.com",
      "category_within_source": "General",
      "source_domain": "www.timothysykes.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.924612"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.803337"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.927030"
        }
      ],
      "overall_sentiment_score": 0.517904,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.509576",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks warrants delisted by NYSE for low trading price",
      "url": "https://www.investing.com/news/company-news/ginkgo-bioworks-warrants-delisted-by-nyse-for-low-trading-price-93CH-3601807",
      "time_published": "20240904T173400",
      "authors": [
        "Investing.com"
      ],
      "summary": "Ginkgo Bioworks' public warrants have been delisted by the NYSE due to \"abnormally low\" trading prices, effective Monday. This delisting does not impact the company's Class A common stock, which continues to trade under the ticker \"DNA.\" The company recently regained compliance with NYSE minimum price criteria for its common stock and has made strategic adjustments like a reverse stock split and cost reduction efforts.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.841323"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.942945"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.919755"
        }
      ],
      "overall_sentiment_score": -0.212158,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.231703",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks regains NYSE compliance, warrants delisted",
      "url": "https://www.investing.com/news/company-news/ginkgo-bioworks-regains-nyse-compliance-warrants-delisted-93CH-3601639",
      "time_published": "20240904T163700",
      "authors": [
        "Investing.com"
      ],
      "summary": "Ginkgo Bioworks Holdings, Inc. has regained compliance with NYSE listing standards after its Class A common stock maintained a price above the $1.00 minimum requirement following a 1-for-40 reverse stock split. Concurrently, the NYSE initiated procedures to delist Ginkgo's public warrants due to their \"abnormally low\" trading price levels. Despite these developments, including adjusted stock targets from BTIG and Goldman Sachs, Ginkgo reaffirmed its full-year guidance and is implementing cost reduction strategies.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.945341"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.800494"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.729759"
        },
        {
          "topic": "finance",
          "relevance_score": "0.630006"
        }
      ],
      "overall_sentiment_score": 0.009242,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.048545",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ginkgo Regains Compliance with NYSE Minimum Bid Price Requirement",
      "url": "https://www.prnewswire.com/news-releases/ginkgo-regains-compliance-with-nyse-minimum-bid-price-requirement-302238512.html",
      "time_published": "20240904T163000",
      "authors": [],
      "summary": "Ginkgo Bioworks Holdings, Inc. announced that it has regained compliance with the NYSE's minimum bid price requirement after its Class A common stock closed above $1.00 for the last day of August and maintained a 30-day trading average above $1.00. This follows a previous notification of non-compliance in May 2024 and a 1-for-40 reverse stock split. However, the NYSE will initiate proceedings to delist Ginkgo's public warrants due to abnormally low trading price levels, although trading in the Class A Common Stock (DNA) will continue unaffected.",
      "banner_image": "https://mma.prnewswire.com/media/1583909/Ginkgo_Logo_Lockup.jpg?w=300",
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.905395"
        }
      ],
      "overall_sentiment_score": 0.224064,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "0.998489",
          "ticker_sentiment_score": "0.241354",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Ginkgo Regains Compliance with NYSE Minimum Bid Price Requirement",
      "url": "https://www.lelezard.com/en/news-21511857.html",
      "time_published": "20240904T163000",
      "authors": [],
      "summary": "Ginkgo Bioworks Holdings, Inc. announced compliance with the NYSE minimum bid price requirement following a letter received on September 3, 2024. This follows a previous notification of non-compliance and a subsequent 1-for-40 reverse stock split. Concurrently, the NYSE will commence proceedings to delist Ginkgo's public warrants due to \"abnormally low\" trading price levels, though trading in its Class A Common Stock remains unaffected.",
      "banner_image": null,
      "source": "Lelezard",
      "category_within_source": "General",
      "source_domain": "Lelezard",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.934415"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.703847"
        },
        {
          "topic": "finance",
          "relevance_score": "0.639972"
        }
      ],
      "overall_sentiment_score": 0.415162,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.392477",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks Securities Litigation Settles for $17.75M",
      "url": "https://www.claimdepot.com/settlements/ginkgo-securities-settlement",
      "time_published": "20240813T165000",
      "authors": [
        "William C. Gendron"
      ],
      "summary": "Ginkgo Bioworks has agreed to a $17.75 million settlement for alleged violations of federal securities laws. Shareholders who purchased or acquired shares between May 11, 2021, and October 5, 2021, may be eligible to claim a portion of the settlement, with an estimated recovery of approximately $0.10 per share before deductions. The deadline to file a claim is November 21, 2024, and a final approval hearing is scheduled for December 5, 2024.",
      "banner_image": null,
      "source": "Claim Depot",
      "category_within_source": "General",
      "source_domain": "Claim Depot",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.926079"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.708794"
        }
      ],
      "overall_sentiment_score": -0.202906,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.232386",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks Reports Second Quarter 2024 Financial Results",
      "url": "https://aijourn.com/ginkgo-bioworks-reports-second-quarter-2024-financial-results/",
      "time_published": "20240808T173000",
      "authors": [
        "Cision PR Newswire"
      ],
      "summary": "Ginkgo Bioworks announced its second-quarter 2024 financial results, reporting a total revenue of $56 million, down 30% from the prior year, primarily due to a reduction in K-12 biosecurity testing. The company provided an update on its restructuring process, expecting over $85 million in annualized cost savings by mid-2025 following a reduction in force impacting 35% of its workforce. Ginkgo reaffirmed its full-year 2024 total revenue outlook of $170 \u2013 $190 million and highlighted new customer contracts and strategic collaborations.",
      "banner_image": null,
      "source": "The AI Journal",
      "category_within_source": "General",
      "source_domain": "The AI Journal",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.934813"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.710858"
        }
      ],
      "overall_sentiment_score": 0.088584,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.091611",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks to Hold Special Meeting of Shareholders",
      "url": "https://www.prnewswire.com/news-releases/ginkgo-bioworks-to-hold-special-meeting-of-shareholders-302210173.html",
      "time_published": "20240802T050824",
      "authors": [
        "NULL"
      ],
      "summary": "Ginkgo Bioworks Holdings, Inc. announced a special virtual meeting of shareholders for August 14, 2024, at 4:00 pm ET. Shareholders will vote on a proposed reverse stock split of Class A and Class B common stock, with a ratio between 1:20 and 1:40. Additionally, they will approve an Amended and Restated Certificate of Incorporation to permit officer exculpation and remove outdated merger provisions.",
      "banner_image": "NULL",
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.909111"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.839631"
        },
        {
          "topic": "technology",
          "relevance_score": "0.624127"
        }
      ],
      "overall_sentiment_score": 0.032243,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "0.320832",
          "ticker_sentiment_score": "0.009986",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks director Shyam Sankar buys $514,750 in company stock",
      "url": "https://www.investing.com/news/company-news/ginkgo-bioworks-director-shyam-sankar-buys-514750-in-company-stock-3445176",
      "time_published": "20240516T171200",
      "authors": [
        "Investing.com"
      ],
      "summary": "Ginkgo Bioworks director Shyam Sankar purchased 625,000 shares of the company's Class A Common Stock for a total of $514,750, as detailed in a recent SEC filing. This acquisition, executed at a weighted average price of $0.8236 per share, increases Sankar's direct ownership to over 2.3 million shares, signaling strong insider confidence despite the company's recent stock performance challenges. InvestingPro insights note Ginkgo Bioworks' financial stability with more cash than debt but also highlight anticipated sales decline and unprofitability for the current year.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.924476"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.840375"
        },
        {
          "topic": "finance",
          "relevance_score": "0.705744"
        }
      ],
      "overall_sentiment_score": 0.353559,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.375668",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "QL AG Announces Partnership with Ginkgo Bioworks to Develop Dairy Proteins",
      "url": "https://www.stocktitan.net/news/DNA/ql-ag-announces-partnership-with-ginkgo-bioworks-to-develop-dairy-xgllq4uybq8n.html",
      "time_published": "20231012T070100",
      "authors": [],
      "summary": "QL AG has announced a partnership with Ginkgo Bioworks to develop dairy proteins using Ginkgo's cell programming platform. This collaboration aims to produce high-quality, nutritionally equivalent dairy proteins through fermentation, addressing challenges in taste, texture, and sustainability faced by the conventional dairy industry and current alternative options. The initiative seeks to reduce production costs and improve the functionality of alternative dairy products.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943427"
        },
        {
          "topic": "technology",
          "relevance_score": "0.809546"
        }
      ],
      "overall_sentiment_score": 0.307598,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.325966",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity",
      "url": "https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-google-cloud-partner-to-build-next-generation-ai-platform-for-biological-engineering-and-biosecurity-301912283.html",
      "time_published": "20230829T080000",
      "authors": [],
      "summary": "Ginkgo Bioworks and Google Cloud have announced a five-year strategic partnership to develop an AI platform for biological engineering and biosecurity. Ginkgo will leverage Google Cloud's Vertex AI and computational infrastructure to build new large language models across genomics, protein function, and synthetic biology, with Google Cloud providing funding and positioning Ginkgo as a key partner in developing foundation models for life sciences. This collaboration aims to accelerate innovation in areas like drug discovery, agriculture, manufacturing, and biosecurity, and will be discussed further at Google Cloud Next.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "technology",
          "relevance_score": "0.930601"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.836265"
        }
      ],
      "overall_sentiment_score": 0.23364,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.443504",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "GOOGL",
          "relevance_score": "0.820957",
          "ticker_sentiment_score": "0.323564",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.771239",
          "ticker_sentiment_score": "0.292628",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.579151",
          "ticker_sentiment_score": "0.125612",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRK",
          "relevance_score": "0.561621",
          "ticker_sentiment_score": "0.107475",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks Announces Proposed Public Offering of Class A Common Stock",
      "url": "https://investingnews.com/ginkgo-bioworks-announces-proposed-public-offering-of-class-a-common-stock/",
      "time_published": "20221115T050913",
      "authors": [
        "NULL"
      ],
      "summary": "Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) announced its intent to offer and sell $100 million of its Class A common stock in an underwritten public offering, with an option for the underwriter to purchase an additional $15 million. The net proceeds will primarily offset cash used for the acquisition of certain assets and liabilities from Bayer CropScience LP and for general corporate purposes. BTIG, LLC is acting as the sole book-running manager for the offering.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=29654697&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.819042"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.930571"
        }
      ],
      "overall_sentiment_score": -0.137864,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.145881",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks Completes Acquisition of Zymergen",
      "url": "https://www.prnewswire.com/news-releases/ginkgo-bioworks-completes-acquisition-of-zymergen-301653624.html",
      "time_published": "20221019T090800",
      "authors": [],
      "summary": "Ginkgo Bioworks announced it has completed its acquisition of Zymergen, a move expected to significantly enhance Ginkgo's platform with integrated automation, software capabilities, and diverse biological engineering experience. Under the merger agreement, Zymergen stockholders received 0.9179 shares of Ginkgo Class A common stock for each Zymergen share, and Zymergen shares will no longer trade on Nasdaq. This acquisition aims to bolster Ginkgo's position as a leading cell programming platform.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.835962"
        },
        {
          "topic": "technology",
          "relevance_score": "0.637124"
        }
      ],
      "overall_sentiment_score": 0.536069,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.537013",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks Signs Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform",
      "url": "https://www.prnewswire.com/news-releases/ginkgo-bioworks-signs-definitive-agreement-to-acquire-fgen-ag-a-leading-bioengineering-company-and-its-proprietary-ultra-high-throughput-screening-platform-301501614.html",
      "time_published": "20220314T070000",
      "authors": [],
      "summary": "Ginkgo Bioworks announced a definitive agreement to acquire FGen AG, a Swiss bioengineering company known for its ultra-high-throughput (uHT) screening platform. This acquisition aims to significantly enhance Ginkgo's cell screening capabilities and expand its genetic exploration, integrating FGen's technology into Ginkgo's strain development engine. The deal is expected to increase the capacity to analyze millions of genetic prototypes, improving the quality of candidate hits for various biotechnological applications.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.948921"
        },
        {
          "topic": "technology",
          "relevance_score": "0.702313"
        }
      ],
      "overall_sentiment_score": 0.452582,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.495081",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "LAWSUIT FILED \u2013 Ginkgo Bioworks Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information",
      "url": "https://finance.yahoo.com/news/lawsuit-filed-ginkgo-bioworks-sued-213100577.html",
      "time_published": "20211118T213100",
      "authors": [],
      "summary": "Block & Leviton LLP announced a class action lawsuit filed against Ginkgo Bioworks Holdings, Inc. for alleged securities law violations. The lawsuit follows a short seller report from Scorpion Capital claiming Ginkgo Bioworks is a \"colossal scam\" and dependent on related party transactions, which led to a 20% drop in stock value. Investors who purchased Ginkgo Bioworks stock between May 11, 2021, and October 5, 2021, are encouraged to contact Block & Leviton before the January 17, 2022, deadline to seek appointment as lead plaintiff.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.942399"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.705210"
        }
      ],
      "overall_sentiment_score": -0.630022,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.610313",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Ginkgo Bioworks Holdings, Inc.",
      "url": "https://finance.yahoo.com/news/equity-alert-levi-korsinsky-llp-183500842.html",
      "time_published": "20211007T183500",
      "authors": [],
      "summary": "Levi & Korsinsky, LLP has launched an investigation into Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) regarding potential securities fraud violations by its officers and directors. This follows a report by Scorpion Capital alleging that Ginkgo Bioworks is a \"colossal scam\" with a \"shell game\" business model heavily reliant on related-party transactions, causing a 20% stock drop. The firm is seeking investors who wish to obtain more information about the investigation.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.909327"
        },
        {
          "topic": "finance",
          "relevance_score": "0.749834"
        }
      ],
      "overall_sentiment_score": -0.600323,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.617070",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Ginkgo Bioworks to Begin Trading Today as NYSE: DNA with Over $1.6 Billion in Proceeds",
      "url": "https://www.prnewswire.com/news-releases/ginkgo-bioworks-to-begin-trading-today-as-nyse-dna-with-over-1-6-billion-in-proceeds-301379315.html",
      "time_published": "20210917T070000",
      "authors": [],
      "summary": "Ginkgo Bioworks announced the closing of its business combination with Soaring Eagle Acquisition Corp., resulting in over $1.6 billion in proceeds and a $15 billion enterprise valuation. The combined company's shares will begin trading today on the NYSE under the ticker symbols \"DNA\" and \"DNA.WS\". This capital is expected to fund the growth of Ginkgo's cell programming platform, with new board members including Dr. Arie Belldegrun, Reshma Kewalramani, and Harry Sloan.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "ipo",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.921987"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.848698"
        }
      ],
      "overall_sentiment_score": 0.318063,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DNA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.475969",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.615649",
          "ticker_sentiment_score": "0.331956",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BEN",
          "relevance_score": "0.571128",
          "ticker_sentiment_score": "0.240209",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    }
  ]
}